Related Experiment Video

Updated: Jun 16, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Treatment of platinum-resistant recurrent ovarian cancer using a "predictive molecule targeted routine chemotherapy"

Xiao-dong Zhao1, Feng-hua Wei, Yi Zhang

  • 1Department of Obstetrics and Gynecology, Beijing Hospital, Beijing, China. sparkling8027@sina.com.cn

Chinese Medical Journal
|January 23, 2010
PubMed
Abstract

Insights

Predictive molecule targeted routine chemotherapy improves outcomes for platinum-resistant recurrent ovarian cancer. This method enhances drug selection, leading to higher response rates and longer overall survival compared to traditional approaches.

Area of Science:

  • Oncology
  • Chemotherapy
  • Drug Discovery

Background:

  • Chemotherapy drug selection is challenging for platinum-resistant recurrent ovarian cancer.
  • Current methods rely on clinical trials and experience, often yielding poor results.
  • A novel approach, predictive molecule targeted routine chemotherapy, is proposed.

Purpose of the Study:

  • To evaluate the efficacy of predictive molecule targeted routine chemotherapy.
  • To compare this new method against standard experience-based treatment for ovarian cancer.

Main Methods:

  • Prospective study of 26 platinum-resistant recurrent ovarian cancer patients using predictive molecule expression for drug selection.
  • Immunohistochemistry used to assess 6 predictive molecules (including p53).
  • Comparison with a control group of 18 patients treated by experience.

Main Results:

  • Response rate to second-line chemotherapy was 77% in the targeted group vs. 28% in the control group (P=0.002).
  • Response rate to third-line chemotherapy was 33% in the targeted group vs. 14% in the control group (P=0.268).
  • Median overall survival was significantly longer in the targeted group (88 weeks) than the control group (56 weeks) (P=0.0315).

Conclusions:

  • Predictive molecule targeted routine chemotherapy is an effective strategy for platinum-resistant recurrent ovarian cancer.
  • This targeted approach improves chemotherapy outcomes.
  • Personalized drug selection based on tumor biomarkers shows promise.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...